5.66
0.12 (2.17%)
| Previous Close | 5.54 |
| Open | 5.55 |
| Volume | 90,938 |
| Avg. Volume (3M) | 1,139,850 |
| Market Cap | 568,056,000 |
| Price / Sales | 651.62 |
| Price / Book | 2.95 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Operating Margin (TTM) | -1,621.58% |
| Diluted EPS (TTM) | -1.39 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 4.72% |
| Current Ratio (MRQ) | 9.08 |
| Operating Cash Flow (TTM) | -56.39 M |
| Levered Free Cash Flow (TTM) | -30.34 M |
| Return on Assets (TTM) | -41.77% |
| Return on Equity (TTM) | -71.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Shattuck Labs, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| Macro Environment | -0.8 |
| AI Insight | NA |
| Weighted Average | -0.83 |
Select this tab to load the latest available analysis.
|
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 14.36% |
| % Held by Institutions | 64.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 30 Jun 2026 | 6,892,033 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |